RxDoctor Payments Data

Rukmini Konatalapalli, MD

Rheumatology · Greenbelt, MDNPI 1053500074

Payments from drug & device makers

$6,658in general payments, 2019–2025

Across 373 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Scilex Pharmaceuticals Inc.$944
  • Novartis$463
  • Johnson & Johnson$429
  • ANI Pharmaceuticals, Inc.$325
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,53898%
  • Education$1202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,658 in reported general payments places this provider in the 60th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$622,719
Medicare patients
589
Services billed
58,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab48$398,099
RinvoqUpadacitinib37$268,096
Xeljanz XrTofacitinib Citrate26$174,116
Humira(Cf)Adalimumab12$86,465
Humira PenAdalimumab12$82,486
Orencia ClickjectAbatacept12$69,838
Adalimumab-Adaz(Cf) PenAdalimumab-Adaz11$23,453
Lidocaine50$12,092
Colchicine83$7,261
MethotrexateMethotrexate Sodium140$5,623
Leflunomide62$3,796
Hydroxychloroquine Sulfate73$3,420
Prednisone386$1,737
Celecoxib42$1,613
Duloxetine Hcl60$1,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$1,167$354,56149 claims
Scilex Pharmaceuticals Inc.Colchicine$944$7,26183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 173 rheumatology providers in Maryland.

Other rheumatology in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →